Revenue Projections - Net revenue for Q4 2025 is expected to be between $27.2 million and $27.7 million, representing a year-over-year increase of approximately 3% to 5% compared to $26.3 million in Q4 2024[4]. - Full year 2025 net revenue is projected to be in the range of $102.7 million to $103.2 million, reflecting a growth of approximately 19% compared to $86.7 million in 2024[4]. - Excluding BIASURGE sales from Q4 2024, net revenue for Q4 2025 is expected to increase approximately 11% to 13% year-over-year[4]. - Full year 2026 net revenue is expected to range from $116 million to $121 million, indicating growth of approximately 13% to 17% compared to the midpoint of the expected net revenue for 2025[5]. - The expected net revenue growth for 2026 is primarily driven by sales of soft tissue products[5]. Financial Position - The company had cash of approximately $16.6 million and long-term debt of $46.0 million as of December 31, 2025, compared to cash of $15.9 million and long-term debt of $30.7 million as of December 31, 2024[4]. Product Development and Market Strategy - The company plans to introduce the OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. market in Q1 2027, pending FDA clearance[4]. - BIASURGE received an Innovative Technology contract from Vizient, expanding access to the product at contracted pricing effective January 1, 2026[4]. - The company aims to enhance its sales and distribution network while expanding its product portfolio through initiatives with Biomimetic Innovations Ltd[5]. - The company is positioned as a pure play surgical business, targeting sustainable long-term growth in the multi-billion-dollar surgical solutions market[5].

FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported certain unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance for the ful ...

Core Insights - Sanara MedTech's BIASURGE Advanced Surgical Solution has been awarded an Innovative Technology contract by Vizient, indicating its potential to improve healthcare outcomes and reduce costs in the surgical market [1][3][4] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare expenditures in the surgical market [7][8] - The company offers a range of surgical products, including BIASURGE, CellerateRX Surgical Activated Collagen Powder, and FORTIFY TRG Tissue Repair Graft, among others [8] Product Details - BIASURGE is a no-rinse irrigation solution designed for efficient surgical cleansing, featuring an antimicrobial preservative that provides broad-spectrum effectiveness against pathogenic microorganisms [5][6] - The product is optimized for pH, viscosity, and osmolality to ensure maximum performance while maintaining safety and effectiveness [5] - BIASURGE enhances surgical precision and visibility by maintaining a cleaner operative field, supporting infection-control strategies [6] Contract Significance - The Innovative Technology contract allows Vizient's extensive network of healthcare facilities to access BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026 [3][4] - The contract was awarded based on recommendations from hospital experts, highlighting BIASURGE's unique benefits over existing market products [3][4]

Core Insights - Sanara MedTech Inc. plans to launch OsStic Synthetic Injectable Structural Bio-Adhesive in the U.S. market in Q1 2027, following FDA clearance [1][2] - OsStic has received Breakthrough Device Designation from the FDA, indicating its potential to improve treatment for serious conditions [2] - The product is expected to be the first bone bioadhesive in the U.S. utilizing phosphoserine, α-TCP, and calcium silicate, offering significant advantages over traditional methods [2][3] Product Development and Regulatory Milestones - Sanara and Biomimetic Innovations Ltd (BMI) have achieved significant milestones in product development, clinical trials, and regulatory processes throughout 2025 [3] - The U.S. Patent and Trademark Office granted a patent for OsStic, ensuring protection of its key ingredients and applications until at least 2037 [3][6] - The partnership between Sanara and BMI includes an exclusive license and distribution agreement, enhancing Sanara's market position in orthopedic care [5][6] Market Need and Innovation - OsStic addresses critical limitations in current provisional fixation techniques, providing forty times stronger bonding than traditional calcium phosphate bone cement [2][3] - The product aims to meet the unmet clinical needs in complex joint reconstruction, offering a paradigm shift in treating previously non-repairable fractures [3] - Sanara's commitment to innovation is reflected in its collaboration with BMI to introduce OsStic as a new standard in bone bioadhesives [4]

Core Insights - Shares of Sanara MedTech Inc. (SMTI) have sharply declined following the release of the company's Q3 earnings, with a nearly 40% drop for the year [1] Company Performance - The surgical segment of Sanara MedTech has been fast-growing and profitable, but this growth has been overshadowed by recent stock performance [1]

Company Overview - Shares of Sanara MedTech Inc. (SMTI) have declined sharply, down nearly 40% for the year following the release of the company's Q3 earnings [1] Financial Performance - The company's fast-growing and profitable surgical segment has been overshadowed, indicating potential underlying issues despite growth in this area [1]

Core Insights - Holzer & Holzer, LLC is investigating whether Sanara MedTech Inc. complied with federal securities laws following the announcement of a strategic realignment that included discontinuing operations of Tissue Health Plus to improve operating efficiency and reallocate resources to its core surgical business [1] - The announcement led to a decline in Sanara's stock price [1] Company Overview - Sanara MedTech Inc. is publicly traded on NASDAQ under the ticker SMTI [1] - The company is focusing on enhancing its core surgical business by discontinuing less efficient operations [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Viewpoint - Glancy Prongay & Murray LLP has initiated an investigation into Sanara MedTech Inc. regarding potential violations of federal securities laws, indicating concerns about the company's compliance and the impact on investors [1]. Company Summary - Sanara MedTech Inc. (NASDAQ: SMTI) is currently under scrutiny for possible legal issues that may affect its investors [1]. - The investigation is aimed at assessing the extent of any violations and the implications for shareholders who may have incurred losses [1].

Core Viewpoint - Sanara MedTech Inc. is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1]. Investigation Details - The investigation is initiated by the Law Offices of Frank R. Cruz on behalf of investors [1]. - The announcement regarding the investigation was made on November 11, 2025, after market hours [1].

Core Viewpoint - Sanara MedTech Inc. is participating in the Piper Sandler 37th Annual Healthcare Conference, presenting on December 3, 2025, to discuss its transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market [1] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing technologies that enhance clinical outcomes while lowering healthcare expenditures in the surgical market [3] - The company markets and distributes a range of surgical products, including CellerateRX Surgical Activated Collagen Powder and FORTIFY TRG Tissue Repair Graft, primarily in the North American surgical tissue repair markets [3] - Sanara aims to be a leading provider of innovative surgical solutions and is committed to expanding its product offerings for patients in the United States [3]